

Joint Press Release Bidiphar and Crearene



Crearene

Bidiphar and Crearene agree to work on Innovative Treatments for the Dialysis Market

Binh Dinh Pharmaceutical and Medical Equipment JSC, Bidiphar, headquartered in Quy Nhon, one of the market leaders in dialysis treatments in the Vietnamese market, and Crearene AG, based in Frauenfeld, Switzerland, have agreed on a memo of understanding (MOU) for the development of creatine-based treatment solutions in dialysis treatments with a view to signing a license agreement.

Ms. Pham Thi Thanh Huong (General Director Bidiphar): “The improvement of the quality of life for dialysis patients will be the focus of this very promising cooperation with Crearene AG. Scientific research and numerous studies demonstrate that dialysis patients are depleted in their creatine levels and therefore cope with significant health impediments, such as fatigue or weak muscles. By adding creatine into the dialysis treatment Bidiphar and Crearene want to improve the quality of life of dialysis patients. Bidiphar aims to continue to build its market leading position in dialysis in the Vietnamese market.”

Dr. Frank Heideloff (CEO, Crearene AG) explains: “Today, there are more than 3 million dialysis patients globally who rely on regular treatment. In some established healthcare markets, governments have already highlighted a need for increased efforts in research to improve dialysis treatments from a patient perspective. We are very happy to work with Bidiphar to bring an innovation to the market, improving general physical conditions and wellbeing of the increasing number of dialysis patients. The patented know-how of Crearene, result of many years of research on the use of creatine, in combination with the manufacturing excellence, patient reach, and market know-how of Bidiphar in Vietnam are an excellent base for this undertaking.”

Weblinks:

www.bidiphar.com

www.crearene.com